Compare Nebius Group NV (NBIS) vs Novo Nordisk A/S (NVO) Price & Performance

Nebius Group NVTrade

Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Nebius Group NV vs Novo Nordisk A/S — how do they compare? Nebius Group NV trades at $218.2 (market cap $46.37B), while Novo Nordisk A/S trades at $49.32 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 4.8× Nebius Group NV's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals.

	NBIS	NVO
Market Cap	$46.37B	$220.53B
Sector	Technology	Health
52-Week High	$286.69	$71.70
52-Week Low	$50.40	$35.29
Enterprise Value	$46.56B	$239.49B
Dividend Yield	—	3.63%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nebius Group NV

NBIS stock surged 22.06% to $216.92 on July 21, 2026, driven by NVIDIA's disclosure of a 9.3% stake, signaling strong AI cloud partnership potential. Despite a bearish technical signal, the company shows robust revenue growth projections, with 2026 net income margin expected at 93.08%. Recent earnings beat expectations in two of the last three quarters, though cash flow trends highlight significant investing outflows.

The outlook is bullish based on analyst consensus and strategic alliances, but risks include high valuation multiples and competitive pressures from tech giants. Investment opportunity centers on AI infrastructure demand, while caution is advised due to volatility and execution risks in scaling operations.

Novo Nordisk A/S

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NBIS

Nebius shares jump 13% after Nvidia reveals 9.3% stake, deepening AI partnership.Proactive Investors · 10 hours agoBullish Nvidia invests $2B in Nebius, Samsung launches Galaxy Card, Cracker Barrel beats revenue outlook.Seeking Alpha · 15 hours agoBullish Nebius shares jump as Nvidia reveals 9.3% stake in Dutch AI cloud companyCNBC · 16 hours agoBullish View details →

NVO

Novo Nordisk sues Eli Lilly over misleading GLP-1 drug ads claiming superior weight-loss results.Proactive Investors · 11 hours agoBearish Novo Nordisk sues Eli Lilly over misleading ads on obesity and diabetes drug efficacy.CNBC · 15 hours agoBearish Novo Nordisk shares jump 27% on strong sales of oral Wegovy and market expansion.Seeking Alpha · 1 day agoBullish View details →

About Nebius Group NV

Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.